{"id":249992,"date":"2023-04-11T00:00:00","date_gmt":"2023-04-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/sptocg0016-2023-biopharma-schizophrenia-special-topics-special-topics\/"},"modified":"2026-03-31T10:34:04","modified_gmt":"2026-03-31T10:34:04","slug":"sptocg0016-2023-biopharma-schizophrenia-special-topics-special-topics-novel-drugs-in-psychiatry-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptocg0016-2023-biopharma-schizophrenia-special-topics-special-topics-novel-drugs-in-psychiatry-us\/","title":{"rendered":"Schizophrenia &#8211; Special Topics &#8211; Special Topics: Novel Drugs in Psychiatry (US)"},"content":{"rendered":"<p>Drugs with novel mechanisms of action are needed for the management of psychiatric patients refractory to current therapies (e.g., patients with treatment-resistant depression [<abbr title=\"treatment-resistant depression\">TRD<\/abbr>], moderate to severe post-traumatic stress disorder [<abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr>]), as well as for the psychiatric conditions with no approved treatment options (e.g., cognitive impairment associated with schizophrenia [<abbr title=\"cognitive impairment associated with schizophrenia\">CIAS<\/abbr>]). Given the sizeable patient populations and the high unmet need for therapies for these difficult-to-treat psychiatric patients, many drug developers have shifted their focus toward novel drug classes, and some novel drugs have reached late phases of development. Of note, psychedelics are one of the emerging drug classes, and two drugs belonging to this class are in Phase III development (i.e., Multidisciplinary Association for Psychedelic Studies\u2019 MDMA-assisted psychotherapy for moderate to severe <abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr> and COMPASS Pathways\u2019 COMP360 psilocybin for <abbr title=\"treatment-resistant depression\">TRD<\/abbr>). Other promising late-phase novel agents include Boehringer Ingelheim\u2019s iclepertin (a glycine transporter-1 inhibitor for <abbr title=\"cognitive impairment associated with schizophrenia\">CIAS<\/abbr>) and Biogen \/ Sage Therapeutics\u2019 zuranolone (a <abbr title=\"gamma-aminobutyric acid\">GABA<\/abbr> receptor modulator for the episodic treatment of major depressive disorder [<abbr title=\"major depressive disorder\">MDD<\/abbr>]). These therapies have the potential to disrupt treatment pathways for their respective patient segments in targeted indications.<\/p>\n<p><strong>Questions answered <\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are psychiatrists\u2019 estimates for patients nonresponsive to current therapies for <abbr title=\"cognitive impairment associated with schizophrenia\">CIAS<\/abbr>, moderate to severe <abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr>, or <abbr title=\"major depressive disorder\">MDD<\/abbr>?<\/li>\n<li>What are physician-perceived advantages and disadvantages of novel emerging drugs in psychiatry such as iclepertin in <abbr title=\"cognitive impairment associated with schizophrenia\">CIAS<\/abbr>, MDMA-assisted psychotherapy in moderate to severe <abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr>, zuranolone in <abbr title=\"major depressive disorder\">MDD<\/abbr>, and COMP360 psilocybin in <abbr title=\"treatment-resistant depression\">TRD<\/abbr>?<\/li>\n<li>How do psychiatrists anticipate prescribing (e.g., which line of therapy) these emerging drugs?<\/li>\n<li>To what maximum percentage of their patients would psychiatrists prescribe these novel drugs, and what factors will persuade them to prescribe these drugs to more of their patients?<\/li>\n<li>What is the physician level of agreement on psychedelic drugs\u2019 potential to manage difficult-to-treat psychiatric conditions?<\/li>\n<\/ul>\n<p><strong>Product description <\/strong><\/p>\n<p>Clarivate\u2019s Special Topics reports assess key trends in dynamic disease areas. This report on novel drugs in psychiatry will help drug marketers and developers gain needed insight into psychiatrists\u2019 treatment approaches for nonresponding patients, key limiting factors of their prescribing of therapies, the most important attributes for emerging therapies in select psychiatric conditions, and psychiatrists\u2019 perceptions of select emerging therapies for psychiatric conditions, including <abbr title=\"cognitive impairment associated with schizophrenia\">CIAS<\/abbr>, moderate to severe <abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr>, and <abbr title=\"major depressive disorder\">MDD<\/abbr> \/ <abbr title=\"treatment-resistant depression\">TRD<\/abbr>.<\/p>\n<p><strong>Content highlights<\/strong><\/p>\n<p><strong>Geography:<\/strong> United States.<\/p>\n<p><strong>Primary research:<\/strong> Survey of 100 U.S. psychiatrists.<\/p>\n<p><strong>Key drugs covered: <\/strong>Iclepertin (<span class=\"abbreviation-guard\">BI<\/span> 425809), zuranolone (SAGE-217), COMP360 psilocybin, MDMA-assisted psychotherapy.<\/p>\n<p><strong>Key insights provided:<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Patient characteristics.<\/li>\n<li>Physician treatment practices and\/or physician insights on medical practice.<\/li>\n<li>Most important attributes for emerging therapies.<\/li>\n<li>Anticipated use of emerging novel therapies.<\/li>\n<li>Physician perception of psychedelic drugs.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-249992","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psychiatry","biopharma-therapy-areas-schizophrenia","biopharma-product-special-topics-other","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249992","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249992\/revisions"}],"predecessor-version":[{"id":281669,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249992\/revisions\/281669"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}